Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DEGTFWK)

DME Name Mephenytoin 4-hydroxylase (CYP2C19)
Synonyms Fenbendazole monooxygenase (4'-hydroxylating); Cytochrome P450 2C19; Cytochrome P450-11A; Cytochrome P450-254C; CYP2C19; CYPIIC17; CYPIIC19
Gene Name CYP2C19
UniProt ID
CP2CJ_HUMAN
INTEDE ID
DME0021
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Gene ID
1557
EC Number EC: 1.14.14.1
Oxidoreductase
Oxygen paired donor oxidoreductase
Flavin/flavoprotein donor oxidoreductase
EC: 1.14.14.1
Lineage Species: Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Sequence
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV
Function
This enzyme is involved in the metabolism of polyunsaturated fatty acids (PUFA). It catalyzes the hydroxylation of carbon-hydrogen bonds and hydroxylates PUFA specifically at the omega-1 position. Besides, it also catalyzes the epoxidation of double bonds of PUFA and metabolizes plant monoterpenes such as limonene. It is also responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
KEGG Pathway
Arachidonic acid metabolism (hsa00590 )
Chemical carcinogenesis (hsa05204 )
Drug metabolism - cytochrome P450 (hsa00982 )
Linoleic acid metabolism (hsa00591 )
Metabolic pathways (hsa01100 )
Serotonergic synapse (hsa04726 )
Reactome Pathway
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE) (R-HSA-2142816 )
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET) (R-HSA-2142670 )
Xenobiotics (R-HSA-211981 )
CYP2E1 reactions (R-HSA-211999 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DME
186 Approved Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acenocoumarol DMH75KV Thrombosis DB61-GB90 Approved [1]
Adinazolam DMBHO9Y Anxiety disorder 6B00-6B0Z Approved [2]
Albendazole DMYZ57N Worm infection 1F90.Z Approved [3]
Almotriptan malate DMFG5ST Migraine 8A80 Approved [4]
Ambrisentan DMD1QXW Pulmonary arterial hypertension BB01.0 Approved [5]
Amiodarone DMUTEX3 Tachyarrhythmias BC71 Approved [6]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [7]
Amoxicillin DMUYNEI Bacterial infection 1A00-1C4Z Approved [8]
Apixaban DM89JLN Thrombosis DB61-GB90 Approved [9]
Aprepitant DM053KT Depression 6A70-6A7Z Approved [10]
Arformoterol DMYM974 Chronic obstructive pulmonary disease CA22 Approved [11]
Artemether DM48QOT Malaria 1F40-1F45 Approved [12]
Aspirin DM672AH Myocardial infarction BA41-BA43 Approved [13]
Atomoxetine DM5L6HI Attention deficit hyperactivity disorder 6A05.Z Approved [14]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [15]
Azelastine DMXTMBJ Allergic conjunctivitis 9A60.02 Approved [16]
Barbital DMJ8NMC Insomnia 7A00-7A0Z Approved [17]
Benzatropine DMF7EXL Psychomotor agitation MB23.M Approved [18]
Bortezomib DMNO38U Mantle cell lymphoma 2A85.5 Approved [1]
Brivaracetam DMSEPK8 Complex partial seizure 8A68.0 Approved [19]
Bromazepam DMY9TCW Anxiety disorder 6B00-6B0Z Approved [20]
Bromfenac DMKB79O Postoperative inflammation 1A00-CA43.1 Approved [21]
Buflomedil DMG1OPF Peripheral vascular disease BD4Z Approved [22]
Bupivacaine DM4PRFC Anaesthesia 9A78.6 Approved [23]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [24]
Capsaicin DMGMF6V Neuropathic pain 8E43.0 Approved [25]
Carisoprodol DMWR1JC Musculoskeletal disorder FA00-FC0Z Approved [26]
Cenobamate DM8KLU9 Complex partial seizure 8A68.0 Approved [27]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [28]
Chlorpropamide DMPHZQE Non-insulin dependent diabetes 5A11 Approved [29]
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [30]
Cisapride DMY7PED Gastroesophageal reflux disease DA22.Z Approved [31]
Citalopram DM2G9AE Depression 6A70-6A7Z Approved [32]
Clarithromycin DM4M1SG Bacterial infection 1A00-1C4Z Approved [33]
Clobazam - Lundbeck DMW1OQ0 Anxiety disorder 6B00-6B0Z Approved [34]
Clopidogrel DMOL54H Thrombosis DB61-GB90 Approved [35]
Clotiazepam DM59AZT Anxiety disorder 6B00-6B0Z Approved [36]
Clozapine DMFC71L Schizophrenia 6A20 Approved [37]
Cyclophosphamide DM4O2Z7 Solid tumour/cancer 2A00-2F9Z Approved [38]
Dapsone DM4LT8A Pneumocystis pneumonia CA40.20 Approved [39]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [40]
Desogestrel DM27U4Y Contraception QA21 Approved [41]
Dexibuprofen DMFYBD0 Ankylosing spondylitis FA92.0 Approved [42]
Dexlansoprazole DM1DBV5 Erosive esophagitis DA25.0 Approved [43]
Dextromethorphan DMUDJZM Cough MD12 Approved [44]
Diazepam DM08E9O Epilepsy 8A60-8A68 Approved [22]
Diclofenac DMPIHLS Osteoarthritis FA00-FA05 Approved [45]
Diltiazem DMAI7ZV Hypertension BA00-BA04 Approved [46]
Diphenhydramine DMKQTBA Meniere disease AB31.0 Approved [1]
Dopamine DMPGUCF Parkinson disease 8A00.0 Approved [47]
Doxazosin DM9PLRH Hypertension BA00-BA04 Approved [48]
Doxepin DMPI98T Depression 6A70-6A7Z Approved [49]
Enasidenib DM8QXOC Acute myeloid leukaemia 2A60 Approved [50]
Enfuvirtide DM7YPM1 Human immunodeficiency virus infection 1C62 Approved [51]
Escitalopram DMFK9HG Major depressive disorder 6A70.3 Approved [52]
Esomeprazole DM7BN0X Peptic ulcer DA61 Approved [53]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [54]
Estradiol acetate DM07U2A Hormone replacement therapy 8E01 Approved [55]
Estradiol cypionate DM27Z5T Hormone replacement therapy 8E01 Approved [55]
Estradiol valerate DM8MC6O Hormone replacement therapy 8E01 Approved [55]
Ethinyl estradiol DMODJ40 Female hypogonadism GA30.6 Approved [56]
Etravirine DMGV8QU Human immunodeficiency virus-1 infection 1C62 Approved [57]
Famotidine DMRL3AB Peptic ulcer DA61 Approved [58]
Fedratinib hydrochloride DML2DCR Myelofibrosis 2A20.2 Approved [59]
Flibanserin DM70DTN Mood disorder 6A60-6E23 Approved [60]
Flunitrazepam DMGR5Z3 Insomnia 7A00-7A0Z Approved [61]
Fluoxetine DM3PD2C Depression 6A70-6A7Z Approved [62]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [63]
Formoterol DMSOURV Asthma CA23 Approved [11]
Fosphenytoin DMOX3LB Epilepsy 8A60-8A68 Approved [64]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [1]
Gliclazide DMN6QO5 Diabetic complication 5A2Y Approved [65]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [66]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [67]
Haloperidol DM96SE0 Schizophrenia 6A20 Approved [68]
Hexobarbital DMQ314B Anaesthesia 9A78.6 Approved [69]
Ibuprofen DM8VCBE Pain MG30-MG3Z Approved [22]
Ifosfamide DMCT3I8 Solid tumour/cancer 2A00-2F9Z Approved [70]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [71]
Indomethacin DMSC4A7 Rheumatoid arthritis FA20 Approved [1]
Ketobemidone DMM3L6Z Pain MG30-MG3Z Approved [72]
Labetalol DMK8U72 Hypertension BA00-BA04 Approved [73]
Lacosamide DMVM6QR Convulsion 8A68.Z Approved [74]
Lansoprazole DMXYLQ3 Duodenal ulcer DA63 Approved [75]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [76]
Levomilnacipran DMV26S8 Fibromyalgia MG30.01 Approved []
LGX818 DMNQXV8 Melanoma 2C30 Approved [77]
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [78]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [79]
Lorcaserin DMG6OYJ Obesity 5B81 Approved [80]
Lorlatinib DMICDLV Non-small-cell lung cancer 2C25.Y Approved [81]
Lovastatin DM9OZWQ Hypercholesterolaemia 5C80.0 Approved [82]
Lumiracoxib DM1S4AG Knee osteoarthritis FA01 Approved [83]
Macitentan DMP79A1 Cardiovascular disease BA00-BE2Z Approved [84]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [85]
Melatonin DMKWFBT Insomnia 7A00-7A0Z Approved [86]
Meperidine DMX4GND Pain MG30-MG3Z Approved [87]
Mephenytoin DM5UGDK Epilepsy 8A60-8A68 Approved [88]
Meprobamate DMHM93Y Anxiety disorder 6B00-6B0Z Approved [26]
Methadone DMTW6IU Dry cough MD12 Approved [89]
Methsuximide DM6L5VO Epileptic seizures 8A61-8A6Z Approved [90]
Methylphenobarbital DMDSWAG Anxiety disorder 6B00-6B0Z Approved [91]
Metoprolol DMOJ0V6 Hypertension BA00-BA04 Approved [22]
Moclobemide DMNZWL7 Depression 6A70-6A7Z Approved [92]
Naftopidil DMQ8R4E Hypertension BA00-BA04 Approved [93]
Nebivolol DM7F1PA Hypertension BA00-BA04 Approved [94]
Nelfinavir mesylate DMFX6G8 Human immunodeficiency virus infection 1C62 Approved [95]
Nicotine DMWX5CO Nicotine dependence 6C4A.2 Approved [96]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [97]
Norethindrone acetate DMDGCQP Menorrhagia GA20.50 Approved [73]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [98]
Omeprazole DM471KJ Gastroesophageal reflux disease DA22.Z Approved [1]
Ospemifene DMC4GEI Dyspareunia GA12 Approved [99]
Oxiconazole DME7KRM Tinea pedis 1F28.2 Approved [100]
Pantoprazole DMSVOCZ Gastroesophageal reflux disease DA22.Z Approved [101]
Paroxetine DM5PVQE Depression 6A70-6A7Z Approved [102]
Pentamidine DMHZJCG Fungal infection 1F29-1F2F Approved [103]
Pentobarbital DMFNH7L Insomnia 7A00-7A0Z Approved [104]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [105]
Perphenazine DMA4MRX Schizophrenia 6A20 Approved [106]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [107]
Phenobarbital DMXZOCG Seizure disorder 8A6Z Approved [108]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [22]
Piperaquine DMT70RC Malaria 1F40-1F45 Approved [109]
Pipotiazine DMC68DF Schizophrenia 6A20 Approved [110]
Podofilox DMT2EJP Condyloma 1A95 Approved [111]
Prasugrel DM7MT6E Acute coronary syndrome BA41 Approved [112]
Praziquantel DMOU1PK Flatworm infection 1F70-1F86 Approved [113]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [114]
Progesterone DMUY35B Premature labour JB00 Approved [115]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [116]
Promazine DMZAL7W Psychomotor agitation MB23.M Approved [117]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [118]
Propranolol DM79NTF Migraine 8A80 Approved [119]
Quazepam DMY4D87 Insomnia 7A00-7A0Z Approved [120]
Quetiapine DM1N62C Schizophrenia 6A20 Approved [121]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [122]
Rabeprazole DMMZXIW Bacterial infection 1A00-1C4Z Approved [123]
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [124]
Ranitidine DM0GUSX Peptic ulcer DA61 Approved [125]
Rifampicin DM5DSFZ Osteoporosis FB83.0 Approved [126]
Rilpivirine DMJ0QOW Human immunodeficiency virus infection 1C62 Approved [127]
Selegiline hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [128]
Sertraline DM0FB1J Depression 6A70-6A7Z Approved [129]
Sildenafil citrate DMSWJ5X Erectile dysfunction HA01.1 Approved [130]
Simvastatin DM30SGU Hypercholesterolaemia 5C80.0 Approved [82]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [131]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [38]
Temazepam DM02A65 Insomnia 7A00-7A0Z Approved [132]
Teniposide DMLW57T Acute lymphoblastic leukaemia 2A85 Approved [73]
Terbinafine DMI6HUW Fungal infection 1F29-1F2F Approved [133]
Testosterone cypionate DMC1TEV Testosterone deficiency 5A81.1 Approved [115]
Testosterone enanthate DMB6871 Testosterone deficiency 5A81.1 Approved [115]
Testosterone Undecanoate DMZO10Y Hypogonadism 5A61.0 Approved [115]
Thalidomide DM70BU5 Multiple myeloma 2A83 Approved [134]
Thiopental DMGP8AX Anaesthesia 9A78.6 Approved [135]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [136]
Ticlopidine DMO946V Stroke 8B20 Approved [1]
Timolol DM3NXRU High blood pressure BA00 Approved [137]
Tipranavir DM8HJX6 Human immunodeficiency virus infection 1C62 Approved [138]
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [139]
Tolbutamide DM02AWV Non-insulin dependent diabetes 5A11 Approved [140]
Tolperisone DMA2GHJ Muscle spasm MB47.3 Approved [141]
Tolterodine DMSHPW8 Overactive bladder GC50.0 Approved [142]
Trabectedin DMG3Y89 Solid tumour/cancer 2A00-2F9Z Approved [143]
Triclabendazole DMPWGBR Helminth infection 1F90.0 Approved [144]
Trimethadione DM0Q8MZ Epilepsy 8A60-8A68 Approved [145]
Trimipramine DM1SC8M Major depressive disorder 6A70.3 Approved [146]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [147]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [148]
Venlafaxine DMR6QH0 Depression 6A70-6A7Z Approved [149]
Verapamil DMA7PEW Hypertension BA00-BA04 Approved [150]
Vilazodone DM4LECQ Major depressive disorder 6A70.3 Approved [151]
Voriconazole DMAOL2S Invasive aspergillosis 1F20.0 Approved [152]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [153]
Voxelotor DMCS6M5 Sickle-cell disorder 3A51 Approved [59]
Warfarin DMJYCVW Atrial fibrillation BC81.3 Approved [154]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [22]
Zolpidem DMWOSKJ Insomnia 7A00-7A0Z Approved [155]
Zonisamide DM0DTF7 Epilepsy 8A60-8A68 Approved [156]
Zotepine DMF3VXA Anxiety disorder 6B00-6B0Z Approved [157]
Aminophenazone DMY2AH1 Anaesthesia 9A78.6 Phase 4 [158]
Benzethonium DMHKZX1 Staphylococcus infection 1B5Y Phase 4 [18]
Etizolam DM8TNX3 Insomnia 7A00-7A0Z Phase 4 [159]
Lynestrenol DM82JP0 N. A. N. A. Phase 4 [160]
Vonoprazan DMCOJPS Gastro-oesophageal reflux DA22 Phase 4 [161]
⏷ Show the Full List of 186 Approved Drug(s)
15 Clinical Trial Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bay 86-9766 DMPW5SB Solid tumour/cancer 2A00-2F9Z Phase 3 [162]
Clomethiazole DMSPN58 Stroke 8B20 Phase 3 [22]
Esketamine DMVU687 Depression 6A70-6A7Z Phase 3 [163]
Momelotinib DMF98Q0 Myelofibrosis 2A20.2 Phase 3 [164]
Muraglitazar DMG3NFZ N. A. N. A. Phase 3 [165]
Nabiximols DMHKJ5I Cancer related pain MG30 Phase 3 [24]
Fexinidazole DMOYE70 Trypanosomiasis 1D51-1F53 Phase 2/3 [166]
BMS 650032 DMQI43G Hepatitis C virus infection 1E51.1 Phase 2 [167]
Ferroquine DMICMXE Malaria 1F40-1F45 Phase 2 [168]
HE3235 DMV50R1 Breast cancer 2C60-2C65 Phase 2 [169]
Indisulam DM9SX6Y Lymphoma 2A80-2A86 Phase 2 [170]
MSC1936369B DMH1DYU Colorectal cancer 2B91.Z Phase 2 [171]
SQ-109 DMWK9BX Bacterial infection 1A00-1C4Z Phase 2 [172]
H3B-6545 DMIFCY2 Breast cancer 2C60-2C65 Phase 1/2 [173]
ITX-5061 DM702MU Human immunodeficiency virus-1 infection 1C62 Phase 1 [174]
⏷ Show the Full List of 15 Clinical Trial Drug(s)
6 Discontinued Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenacetin DMRQAM0 Analgesia MB40.8 Withdrawn from market [175]
GW873140 DMG6TS2 Human immunodeficiency virus-1 infection 1C62 Discontinued in Phase 3 [176]
Seratrodast DMPNTDL Allergic asthma CA23.0 Discontinued in Phase 3 [177]
Benzydamine DMEQL9U Chemotherapy or radiotherapy-induced mucositis DA42-DA60 Discontinued in Phase 2 [67]
Nemifitide DM6VP9U Major depressive disorder 6A70.3 Discontinued in Phase 2 [178]
VR-776 DMFQWNI Premature ejaculation HA03.0Z Discontinued in Phase 1 [179]
⏷ Show the Full List of 6 Discontinued Drug(s)
3 Investigative Drug(s) Metabolized by This DME
Drug Name Drug ID Indication ICD 11 Highest Status REF
Medazepam DMNKSX3 Discovery agent N.A. Investigative [180]
Nordazepam DMHAWYQ Anxiety disorder 6B00-6B0Z Investigative [181]
Phenazone DMCE985 Discovery agent N.A. Investigative [182]

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DME
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Acute myelocytic leukaemia 2B33.1 Bone marrow 6.34E-01 4.42E-03 2.22E-02
Alopecia ED70 Skin from scalp 2.43E-01 5.42E-02 1.47E-01
Alzheimer's disease 8A20 Entorhinal cortex 2.40E-01 -3.31E-02 -1.97E-01
Ankylosing spondylitis FA92.0 Pheripheral blood 6.27E-01 -2.63E-02 -1.68E-01
Aortic stenosis BB70 Calcified aortic valve 9.75E-01 -7.15E-02 -1.02E-01
Apnea 7A40 Hyperplastic tonsil 4.67E-01 7.68E-02 2.20E-01
Arthropathy FA00-FA5Z Peripheral blood 1.76E-01 -7.97E-02 -6.68E-01
Asthma CA23 Nasal and bronchial airway 1.65E-02 -4.37E-02 -7.84E-02
Atopic dermatitis EA80 Skin 8.18E-02 5.11E-02 3.21E-01
Autism 6A02 Whole blood 2.63E-01 -6.81E-02 -4.02E-01
Autoimmune uveitis 9A96 Peripheral monocyte 4.34E-02 -9.83E-02 -5.71E-01
Autosomal dominant monocytopenia 4B04 Whole blood 8.72E-02 3.38E-02 2.42E-01
Bacterial infection of gingival 1C1H Gingival tissue 1.16E-07 -2.81E-01 -7.41E-01
Batten disease 5C56.1 Whole blood 5.80E-01 -3.14E-02 -1.69E-01
Behcet's disease 4A62 Peripheral blood 2.03E-01 1.00E-01 6.91E-01
Bipolar disorder 6A60-6A6Z Prefrontal cortex 1.11E-01 -4.04E-02 -2.22E-01
Bladder cancer 2C94 Bladder tissue 2.77E-05 6.14E-01 3.59E+00
Breast cancer 2C60-2C6Z Breast tissue 3.84E-13 -1.34E-01 -3.71E-01
Cardioembolic stroke 8B11.20 Whole blood 3.79E-01 6.76E-02 3.66E-01
Cervical cancer 2C77 Cervical tissue 4.73E-03 -7.15E-01 -1.21E+00
Childhood onset rheumatic disease FA20.Z Peripheral blood 7.63E-01 -1.26E-02 -9.04E-02
Chronic hepatitis C 1E51.1 Whole blood 7.35E-01 3.90E-02 2.84E-01
Chronic obstructive pulmonary disease CA22 Lung tissue 4.79E-03 1.32E-01 7.85E-01
Chronic obstructive pulmonary disease CA22 Small airway epithelium 1.82E-01 -1.71E-02 -9.86E-02
Chronic rhinosinusitis CA0A Sinus mucosa tissue 1.03E-01 9.55E-02 9.27E-01
Colon cancer 2B90 Colon tissue 1.98E-01 -6.06E-02 -1.56E-01
Coronary artery disease BA80-BA8Z Peripheral blood 2.83E-01 -8.91E-02 -4.03E-01
Diffuse large B-cell lymphoma 2A81 Tonsil tissue 3.46E-01 8.52E-02 5.47E-01
Endometriosis GA10 Endometrium tissue 1.02E-01 2.47E-01 6.15E-01
Familial hypercholesterolemia 5C80.00 Peripheral blood 3.87E-01 2.95E-02 2.13E-01
Familial hypercholesterolemia 5C80.00 Whole blood 4.03E-02 -1.19E-01 -5.11E-01
Gastric cancer 2B72 Gastric tissue 3.38E-01 -5.76E-01 -8.98E-01
Glioblastopma 2A00.00 Nervous tissue 9.91E-02 -6.39E-02 -2.08E-01
Glioma 2A00.0Y-2A00.0Z Brain stem tissue 7.14E-01 -2.20E-02 -3.18E-01
Glioma 2A00.0Y-2A00.0Z White matter tissue 4.16E-04 -6.72E-01 -1.83E+00
Head and neck cancer 2D42 Head and neck tissue 1.49E-08 -1.53E-01 -6.35E-01
HIV-associated neurocognitive impairment 8A2Y-8A2Z White matter tissue 1.72E-01 -4.99E-03 -3.09E-02
Huntington's disease 8A01.10 Whole blood 3.35E-01 1.08E-01 6.56E-01
Idiopathic pulmonary fibrosis CB03.4 Lung tissue 5.67E-01 -4.03E-02 -2.13E-01
Immunodeficiency 4A00-4A20 Peripheral blood 9.70E-01 -1.38E-02 -1.75E-01
Influenza 1E30 Whole blood 7.61E-01 9.45E-02 4.82E-01
Interstitial cystitis GC00.3 Bladder tissue 4.53E-02 -2.16E-01 -2.35E+00
Intracranial aneurysm 8B01.0 Intracranial artery 7.97E-01 -1.01E-01 -4.23E-01
Irritable bowel syndrome DD91.0 Rectal colon tissue 2.16E-02 2.13E-01 4.28E-01
Ischemic stroke 8B11 Peripheral blood 1.72E-01 2.64E-02 2.26E-01
Juvenile idiopathic arthritis FA24 Peripheral blood 3.42E-01 3.89E-02 1.18E-01
Lateral sclerosis 8B60.4 Skin 6.32E-02 1.30E-01 7.89E-01
Lateral sclerosis 8B60.4 Cervical spinal cord 5.49E-01 5.15E-02 1.92E-01
Liver cancer 2C12.0 Liver tissue 4.41E-18 -4.32E+00 -2.45E+00
Liver failure DB99.7-DB99.8 Liver tissue 3.11E-04 -2.33E+00 -2.27E+00
Lung cancer 2C25 Lung tissue 1.08E-02 2.60E-02 1.59E-01
Lupus erythematosus 4A40 Whole blood 6.94E-01 -6.72E-02 -1.65E-01
Major depressive disorder 6A70-6A7Z Hippocampus 7.66E-01 9.19E-03 4.88E-02
Major depressive disorder 6A70-6A7Z Whole blood 5.66E-01 -1.33E-02 -3.98E-02
Melanoma 2C30 Skin 8.42E-01 -1.13E-02 -1.81E-02
Multiple myeloma 2A83.1 Peripheral blood 3.82E-03 1.37E-01 1.05E+00
Multiple myeloma 2A83.1 Bone marrow 3.09E-05 -6.05E-01 -3.19E+00
Multiple sclerosis 8A40 Plasmacytoid dendritic cells 3.44E-01 -1.85E-01 -5.25E-01
Myelodysplastic syndrome 2A36-2A3Z Bone marrow 8.92E-01 -9.92E-03 -4.27E-02
Myelofibrosis 2A20.2 Whole blood 1.74E-01 -1.64E-01 -9.73E-01
Myocardial infarction BA41-BA50 Peripheral blood 2.35E-02 1.96E-01 4.18E-01
Myopathy 8C70.6 Muscle tissue 9.28E-02 -1.96E-01 -1.04E+00
Neonatal sepsis KA60 Whole blood 4.08E-01 2.70E-03 1.32E-02
Neuroectodermal tumour 2A00.11 Brain stem tissue 4.94E-05 -9.30E-01 -2.34E+00
Non-alcoholic fatty liver disease DB92 Liver tissue 2.49E-01 6.65E-01 5.19E-01
Obesity related type 2 diabetes 5A11 Omental adipose tissue 9.55E-02 1.59E-01 1.72E+00
Olive pollen allergy CA08.00 Peripheral blood 8.52E-02 8.13E-02 6.76E-01
Oral cancer 2B6E Oral tissue 6.40E-03 -4.39E-01 -9.19E-01
Osteoarthritis FA00-FA0Z Synovial tissue 5.17E-01 -3.87E-02 -3.88E-01
Osteoporosis FB83.1 Bone marrow 5.44E-01 1.29E-03 1.52E-02
Ovarian cancer 2C73 Ovarian tissue 8.74E-01 -3.97E-02 -1.15E-01
Pancreatic cancer 2C10 Pancreas 7.82E-02 -4.38E-02 -1.55E-01
Parkinson's disease 8A00.0 Substantia nigra tissue 9.62E-01 2.57E-02 1.10E-01
Pediatric respiratory syncytial virus infection CA40.11 Peripheral blood 5.37E-01 -3.22E-02 -3.78E-01
Pituitary cancer 2D12 Pituitary tissue 8.64E-01 -4.67E-03 -1.80E-02
Pituitary gonadotrope tumour 2D12 Pituitary tissue 7.12E-01 6.83E-03 2.98E-02
Polycystic ovary syndrome 5A80.1 Vastus lateralis muscle 3.62E-02 -6.86E-02 -6.03E-01
Polycythemia vera 2A20.4 Whole blood 3.88E-02 2.48E-02 1.36E-01
Pompe disease 5C51.3 Biceps muscle 7.43E-02 -1.55E-01 -6.44E-01
Preterm birth KA21.4Z Myometrium 8.12E-01 -4.32E-02 -2.58E-01
Prostate cancer 2C82 Prostate 1.39E-02 -2.78E-01 -5.67E-01
Psoriasis EA90 Skin 1.39E-04 -1.32E-01 -4.10E-01
Rectal cancer 2B92 Rectal colon tissue 5.51E-02 1.95E-01 1.20E+00
Renal cancer 2C90-2C91 Kidney 1.02E-01 -2.84E-01 -7.34E-01
Retinoblastoma 2D02.2 Uvea 1.72E-03 -2.24E-01 -1.31E+00
Rheumatoid arthritis FA20 Synovial tissue 5.48E-01 1.12E-01 7.24E-01
Rhinovirus infection CA42.1 Nasal epithelium tissue 8.48E-01 1.51E-02 1.06E-01
Schizophrenia 6A20 Prefrontal cortex 7.39E-01 1.54E-02 4.74E-02
Schizophrenia 6A20 Superior temporal cortex 4.64E-02 -8.21E-02 -7.11E-01
Scleroderma 4A42.Z Whole blood 1.73E-01 -6.49E-02 -5.42E-01
Seizure 8A60-8A6Z Whole blood 9.70E-01 -2.22E-02 -1.17E-01
Sensitive skin EK0Z Skin 8.28E-01 -2.95E-02 -1.87E-01
Sepsis with septic shock 1G41 Whole blood 3.26E-03 7.59E-02 3.47E-01
Shwachman-Diamond syndrome 3A70.0 Bone marrow 1.67E-02 8.33E-01 1.75E+00
Sickle cell disease 3A51.0-3A51.3 Peripheral blood 5.89E-01 6.53E-02 3.44E-01
Simpson golabi behmel syndrome LD2C Adipose tissue 4.71E-01 0.00E+00 0.00E+00
Sjogren's syndrome 4A43.2 Salivary gland tissue 6.05E-02 2.38E-01 2.17E+00
Skin cancer 2C30-2C3Z Skin 3.87E-01 -1.26E-02 -3.57E-02
Thrombocythemia 3B63 Whole blood 6.62E-01 1.75E-02 1.07E-01
Thrombocytopenia 3B64 Whole blood 9.71E-01 -2.25E-04 -8.56E-04
Thyroid cancer 2D10 Thyroid 9.10E-03 5.38E-02 2.83E-01
Tibial muscular dystrophy 8C75 Muscle tissue 1.00E-03 1.34E-01 1.10E+00
Tuberous sclerosis complex LD2D.2 Perituberal tissue 1.07E-01 8.50E-02 9.43E-01
Type 2 diabetes 5A11 Liver tissue 1.80E-01 1.81E-02 3.07E-02
Ureter cancer 2C92 Urothelium 2.13E-01 -1.54E-01 -8.59E-01
Uterine cancer 2C78 Endometrium tissue 1.07E-03 -2.00E-01 -3.54E-01
Vitiligo ED63.0 Skin 4.37E-01 0.00E+00 0.00E+00
------------------------------------------------------------------------------------
⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name Mephenytoin 4-hydroxylase DTT Info

References

1 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
2 Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.
3 Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
4 Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
5 Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
6 A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10.
7 A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
8 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
9 Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
10 Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92.
11 A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805.
12 The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36.
13 Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
14 Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26.
15 Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
16 In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6.
17 Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child. 2012 Jun;97(6):569-72.
18 Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53.
19 Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45.
20 Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71.
21 Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
22 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
23 Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.
24 Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730.
25 Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49.
26 Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8.
27 FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
28 Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9.
29 Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63.
30 Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
31 Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
32 Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49.
33 Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73.
34 A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004 Dec;26(8):530-4.
35 Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780.
36 Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6.
37 Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9.
38 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
39 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
40 Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
41 The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82.
42 PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106.
43 Pharmacological and safety profile of dexlansoprazole: a new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66.
44 Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
45 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
46 Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9.
47 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
48 Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8.
49 Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
50 Enasidenib for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760.
51 Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86.
52 Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54.
53 Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200.
54 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
55 Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54.
56 The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7.
57 Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14.
58 Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48.
59 FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration.
60 Flibanserin therapy and CYP2C19 genotype.
61 The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol. 2003 Apr;23(2):169-75.
62 Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001 Jan;22(1):85-90.
63 Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
64 CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009 Dec;49(12):1483-7.
65 The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study. Eur J Med Chem. 2009 Feb;44(2):854-61.
66 Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80.
67 Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica. 2001 Jul;31(7):387-97.
68 In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
69 Stereoselective hexobarbital 3'-hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. Chirality. 2007 Jul;19(7):550-8.
70 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
71 Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7.
72 Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein. Xenobiotica. 2005 Aug;35(8):785-96.
73 Drug Interactions Flockhart Table
74 Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52.
75 Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br J Clin Pharmacol. 2005 Mar;59(3):302-9.
76 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
77 Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018 Mar;30(2):125-133.
78 Advisory committee lofexidine hydrochloride (lucemyratm) briefing document.
79 Advances in high-resolution MS and hepatocyte models solve a long-standing metabolism challenge: the loratadine story. Bioanalysis. 2016 Aug;8(16):1645-62.
80 Identification of human cytochrome P450 and flavin-containing monooxygenase enzymes involved in the metabolism of lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist. Drug Metab Dispos. 2012 Apr;40(4):761-71.
81 FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
82 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
83 Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2005;44(12):1247-66.
84 Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013 Aug;52(8):685-92.
85 Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica. 1996 Mar;26(3):275-84.
86 The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: a randomized, double-blind, placebo-controlled study. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):447-50.
87 Impact of cytochrome P450 variation on meperidine N-demethylation to the neurotoxic metabolite normeperidine. Xenobiotica. 2020 Feb;50(2):209-222.
88 Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
89 Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
90 The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol. 1995 Apr;39(4):441-4.
91 A novel single nucleotide polymorphism (SNP) of the CYP2C19 gene in a Japanese subject with lowered capacity of mephobarbital 4'-hydroxylation. Drug Metab Pharmacokinet. 2004 Jun;19(3):236-8.
92 Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
93 Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
94 Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
95 Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. Br J Clin Pharmacol. 2015 Aug;80(2):267-75.
96 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
97 Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica. 1991 Dec;21(12):1559-70.
98 In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther. 1998 Aug;23(4):247-55.
99 Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 2013;28(3):153-61.
100 In vitro metabolism of oxymetazoline: evidence for bioactivation to a reactive metabolite. Drug Metab Dispos. 2011 Apr;39(4):693-702.
101 Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460.
102 Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
103 Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
104 CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5.
105 Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
106 Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000 Dec;50(6):563-71.
107 An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
108 Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos. 2003 Apr;31(4):421-31.
109 Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014 Dec;58(12):7340-6.
110 Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9.
111 Characterization of in vitro metabolites of deoxypodophyllotoxin in human and rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22(1):52-8.
112 The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012 Nov 12;72(16):2087-116.
113 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
114 Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 Apr;24(2):87-92.
115 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
116 Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur J Clin Pharmacol. 2002 Nov;58(8):543-5.
117 Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol. 2003 Apr;138(8):1465-74.
118 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
119 Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
120 In vitro metabolism of quazepam in human liver and intestine and assessment of drug interactions. Xenobiotica. 2004 Nov-Dec;34(11-12):1001-11.
121 A liquid chromatographic-electrospray-tandem mass spectrometric method for quantitation of quetiapine in human plasma and liver microsomes: application to study in vitro metabolism. J Anal Toxicol. 2004 Sep;28(6):443-8.
122 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
123 Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. Eur J Clin Pharmacol. 2006 Aug;62(8):597-603.
124 Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J Cent Nerv Syst Dis. 2011 Apr 12;3:51-65.
125 Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
126 Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
127 Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2016 Dec 27;61(1).
128 Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003 Sep;31(9):1093-102.
129 Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. Int J Clin Pharm. 2016 Apr;38(2):388-94.
130 Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol. 2001 Mar;51(3):239-48.
131 FDA Label of Diacomit. The 2020 official website of the U.S. Food and Drug Administration.
132 Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
133 Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999 Sep;27(9):1029-38.
134 Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide. Cancer Biol Ther. 2002 Nov-Dec;1(6):669-73.
135 Lerman J. (2014). Neonatal Anesthesia. Springer.
136 CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems. Antimicrob Agents Chemother. 2013 Nov;57(11):5448-56.
137 Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011 May;108(5):297-303.
138 A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42.
139 The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73.
140 CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes. Drug Metab Dispos. 2000 Mar;28(3):354-9.
141 Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes. Drug Metab Dispos. 2003 May;31(5):631-6.
142 Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.
143 In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
144 In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett. 2018;12(2):101-116.
145 Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002 Apr;66(2):185-200.
146 Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
147 In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 2000 Jan;30(1):61-70.
148 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
149 O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999 May;20(5):480-90.
150 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
151 Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P T. 2012 Jan;37(1):28-31.
152 Effect of voriconazole on the pharmacokinetics of diclofenac. Fundam Clin Pharmacol. 2007 Dec;21(6):651-6.
153 Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
154 Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 1;6(3):157-64.
155 Zolpidem extended-release: a single insomnia treatment option for sleep induction and sleep maintenance symptoms. Am J Ther. 2007 May-Jun;14(3):299-305.
156 Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
157 Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica. 1999 Mar;29(3):217-29.
158 Inhibition of human hepatic cytochrome P450s and steroidogenic CYP17 by nonylphenol. Biol Pharm Bull. 2002 Feb;25(2):235-8.
159 Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007 Aug;32(4):333-41.
160 Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008 May;110(1-2):56-66.
161 In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker. Xenobiotica. 2017 Dec;47(12):1027-1034.
162 Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res. 2013 Mar 1;19(5):1232-43.
163 Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2017 Feb 20;2(1):2-10.
164 Pharmacokinetics and disposition of momelotinib revealed a disproportionate human metabolite-resolution for clinical development. Drug Metab Dispos. 2018 Mar;46(3):237-247.
165 Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos. 2007 Jan;35(1):139-49.
166 Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
167 Australian Public Assessment Report for asunaprevir.
168 In vitro metabolism of ferroquine (SSR97193) in animal and human hepatic models and antimalarial activity of major metabolites on Plasmodium falciparum. Drug Metab Dispos. 2006 Apr;34(4):667-82.
169 17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78.
170 CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res. 2007 May 15;13(10):2970-6.
171 Metabolism of the MEK1/2 inhibitor pimasertib involves a novel conjugation with phosphoethanolamine in patients with solid tumors. Drug Metab Dispos. 2017 Feb;45(2):174-182.
172 Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol. 2006 Mar;147(5):476-85.
173 Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
174 ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
175 Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica. 1999 Sep;29(9):885-98.
176 Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother. 2008 Mar;52(3):858-65.
177 Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). Drug Metab Dispos. 1997 Jan;25(1):110-5.
178 Antidepressants: Past, Present and Future. Edited by Sheldon H. Preskorn Christina Y. Stanga John P. Feighner Ruth Ross. Page: 574.
179 Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics. 2017 May;18(7):601-605.
180 Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;(182):335-60.
181 Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 1999 Dec;66(6):642-6.
182 Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.